文献速递肝病消化道肿瘤与早癌

肝细胞癌细胞外囊泡ECG评分:用于检测早期肝细胞癌的细胞外囊泡蛋白检测方法

HCC EV ECG score: An extracellular vesicle-based protein assay for detection of early-stage hepatocellular carcinoma.
PubMed 文献 · Hepatology · 2023-02-17

研究开发了基于细胞外囊泡(EV)表面蛋白的ECG评分,由EpCAM+CD63+、CD147+CD63+和GPC3+CD63+三种HCC EV亚群读数计算,在训练队列(n=106)和独立验证队列(n=72)中评估其区分早期HCC与肝硬化的性能。训练队列AUROC为0.95(95%CI 0.90-0.99),灵敏度91%、特异度90%;验证队列AUROC为0.93(95%CI 0.87-0.99)。

要点

  • HCC EV ECG评分在训练队列区分早期HCC与肝硬化的AUROC为0.95(95%CI 0.90-0.99),灵敏度91%、特异度90%。
  • 验证队列AUROC为0.93(95%CI 0.87-0.99),病毒病因亚组0.95(95%CI 0.90-1.00),非病毒病因亚组0.94(95%CI 0.88-0.99)。
  • 组织微阵列中99.7%至少对四种HCC相关蛋白标志物(EpCAM、CD147、GPC3、ASGPR1)之一染色阳性。

核心结论

  • HCC EV ECG评分在检测早期HCC方面显示出很大潜力,可能增强当前监测方法并改善患者结局。

研究设计与样本

  • 采用组织微阵列评估四种潜在HCC相关蛋白标志物,并开发优化了由共价化学介导的HCC EV纯化和实时免疫聚合酶链反应读数组成的HCC EV表面蛋白检测方法,用于定量EV亚群。
  • 基于三种HCC EV亚群(EpCAM+CD63+、CD147+CD63+和GPC3+CD63+ HCC EV)的读数建立HCC EV ECG评分,用于检测早期HCC。
  • 开展了一项2期生物标志物研究,在训练队列(n=106)和独立验证队列(n=72)中评估ECG评分的性能。

主要发现

  • 训练队列中,HCC EV ECG评分区分早期HCC与肝硬化的AUROC为0.95(95%CI 0.90-0.99),灵敏度91%、特异度90%。
  • 验证队列中AUROC为0.93(95%CI 0.87-0.99);按病因分亚组,病毒病因亚组AUROC为0.95(95%CI 0.90-1.00),非病毒病因亚组AUROC为0.94(95%CI 0.88-0.99)。
  • 组织微阵列中99.7%的样本至少对四种HCC相关蛋白标志物(EpCAM、CD147、GPC3和ASGPR1)之一染色阳性,这些标志物随后在HCC EV中得到验证。

关键数值与推荐

  • HCC EV ECG评分由EpCAM+CD63+、CD147+CD63+和GPC3+CD63+三种HCC EV亚群的读数计算得出。
  • 训练队列中,ECG评分区分早期HCC与肝硬化的AUROC为0.95(95%CI 0.90-0.99),灵敏度91%、特异度90%。
  • 验证队列中AUROC为0.93(95%CI 0.87-0.99);病毒病因亚组0.95(95%CI 0.90-1.00),非病毒病因亚组0.94(95%CI 0.88-0.99)。

临床怎么用

  • 原文结论指出HCC EV ECG评分在检测早期HCC方面显示出很大潜力,可能增强当前监测方法并改善患者结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The sensitivity of current surveillance methods for detecting early-stage hepatocellular carcinoma (HCC) is suboptimal. Extracellular vesicles (EVs) are promising circulating biomarkers for early cancer detection. In this study, we aim to develop an HCC EV-based surface protein assay for early detection of HCC. APPROACH AND RESULTS: Tissue microarray was used to evaluate four potential HCC-associated protein markers. An HCC EV surface protein assay, composed of covalent chemistry-mediated HCC EV purification and real-time immuno-polymerase chain reaction readouts, was developed and optimized for quantifying subpopulations of EVs. An HCC EV ECG score, calculated from the readouts of three HCC EV subpopulations ( E pCAM + CD63 + , C D147 + CD63 + , and G PC3 + CD63 + HCC EVs), was established for detecting early-stage HCC. A phase 2 biomarker study was conducted to evaluate the performance of ECG score in a training cohort ( n = 106) and an independent validation cohort ( n = 72).Overall, 99.7% of tissue microarray stained positive for at least one of the four HCC-associated protein markers (EpCAM, CD147, GPC3, and ASGPR1) that were subsequently validated in HCC EVs. In the training cohort, HCC EV ECG score demonstrated an area under the receiver operating curve (AUROC) of 0.95 (95% confidence interval [CI], 0.90-0.99) for distinguishing early-stage HCC from cirrhosis with a sensitivity of 91% and a specificity of 90%. The AUROCs of the HCC EV ECG score remained excellent in the validation cohort (0.93; 95% CI, 0.87-0.99) and in the subgroups by etiology (viral: 0.95; 95% CI, 0.90-1.00; nonviral: 0.94; 95% CI, 0.88-0.99). CONCLUSION: HCC EV ECG score demonstrated great potential for detecting early-stage HCC. It could augment current surveillance methods and improve patients' outcomes.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Sun N, Zhang C, Lee YT, et al. HCC EV ECG score: An extracellular vesicle-based protein assay for detection of early-stage hepatocellular carcinoma. Hepatology. 2023. PMID: 35908246. doi:10.1002/hep.32692

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。